KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 7,627 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $9.75, for a total value of $74,363.25. Following the completion of the transaction, the chief executive officer now owns 274,596 shares in the company, valued at approximately $2,677,311. This represents a 2.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.
KalVista Pharmaceuticals Price Performance
NASDAQ KALV opened at $9.34 on Tuesday. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.39 and a 1 year high of $16.88. The stock has a market capitalization of $461.58 million, a PE ratio of -2.57 and a beta of 0.85. The business's 50-day moving average is $10.85 and its 200 day moving average is $11.81.
Institutional Investors Weigh In On KalVista Pharmaceuticals
A number of large investors have recently made changes to their positions in the business. Barclays PLC raised its holdings in shares of KalVista Pharmaceuticals by 418.5% during the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company's stock valued at $778,000 after acquiring an additional 54,257 shares in the last quarter. Geode Capital Management LLC increased its position in KalVista Pharmaceuticals by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 830,984 shares of the specialty pharmaceutical company's stock valued at $9,624,000 after purchasing an additional 24,713 shares during the period. Zimmer Partners LP raised its holdings in KalVista Pharmaceuticals by 52.6% in the 3rd quarter. Zimmer Partners LP now owns 95,704 shares of the specialty pharmaceutical company's stock worth $1,108,000 after purchasing an additional 33,000 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of KalVista Pharmaceuticals by 40.3% in the 3rd quarter. Wellington Management Group LLP now owns 117,923 shares of the specialty pharmaceutical company's stock worth $1,366,000 after purchasing an additional 33,900 shares during the period. Finally, State Street Corp boosted its stake in shares of KalVista Pharmaceuticals by 68.1% during the 3rd quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company's stock valued at $14,725,000 after purchasing an additional 515,179 shares in the last quarter.
Wall Street Analyst Weigh In
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
From Weiss Ratings | Ad
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide.
It will give them unprecedented powers to control your bank account.
Learn these 4 simple steps and protect your savings before it’s too late.
KALV has been the topic of several recent research reports. Cantor Fitzgerald restated an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday. Finally, Needham & Company LLC reiterated a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th.
Read Our Latest Analysis on KALV
About KalVista Pharmaceuticals
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
